



Re: Best-Value Biological Medicines; Adalimumab & Etanercept

14 September 2020

Dear Colleagues,

The purpose of this letter is to update you on the best-value biological (BVB) medicine initiative for adalimumab and etanercept. As communicated previously the HSE-Medicines Management Programme (MMP) recommends the following BVB medicines for adalimumab and etanercept:

- Adalimumab:
 - Citrate-containing: **Idacio[®], Imraldi[®]**
 - Citrate-free: **Amgevita[®], Hulio[®]**
- Etanercept: **Benepali[®]**

Since the publication of these recommendations in May 2019, there has been a significant increase in the prescribing of the BVB medicines. In July 2020, **47%** of patients in receipt of adalimumab 40 mg pre-filled pen or syringe, and **50%** of patients in receipt of etanercept 25/50 mg pre-filled pen or syringe were prescribed a BVB medicine. Over 8,700 patients have been initiated on, or switched to a BVB medicine since June 2019.

I would like to take this opportunity to thank those who have embraced this initiative. Prescribing of the BVB medicines is leading to significant savings for the health service, which can facilitate access to new, innovative medicines for patients.

Branded adalimumab or etanercept are substantially more expensive than the BVB medicines. In light of this, it is vital that we redouble our efforts in the coming months to prescribe the BVB medicines, in particular identifying patients who can be switched from the branded products to the BVB medicines. Communication by the HSE Chief Executive Officer (CEO) to Hospital Group CEOs in March 2020, sets a target of a minimum of 80% of patients to be switched to a BVB medicine from branded adalimumab or etanercept by the end of 2020.

In recognition of the efficiencies that result from the prescribing of the BVB medicines, the gain share arrangement is available to consultant-led teams to fund service delivery or enhancement, when they initiate a patient on, or switch them to a BVB medicine.

MMP pharmacists are available to engage with consultants and clinical teams to provide support for initiation of, and switching to the BVB medicines. Please contact the MMP (mmp@hse.ie) if you wish to avail of this support.

Further information on the BVB medicine initiative including information for healthcare professionals, and resources to support initiating patients on, or switching them to the BVB medicines are available on the MMP website (www.hse.ie/yourmedicines) in the section entitled *Best-value biological medicines*.

My thanks for your ongoing support in promoting safe, effective and cost-effective prescribing.

With best wishes,



Professor Michael Barry,
National Clinical Lead,
Medicines Management Programme.
www.hse.ie/yourmedicines